ArticleHeart failure reviews2026
The prospective Austrian hypertrophic cardiomyopathy registry - design, methods and results of the run-in period.
Article in Heart failure reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06368518 (Austrian Hypertrophic Cardiomyopathy Registry), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Austrian Hypertrophic Cardiomyopathy Registry
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis and management of hypertrophic cardiomyopathy (HCM) is increasingly complex, and systematic evidence remains sparse. The Austrian HCM registry aims to provide representative real-world data addressing gaps in evidence. Here, we report design, methods and results after one year enrolment. The Austrian HCM Registry is an ongoing prospective, multicenter registry including University and community hospitals across Austria. Patients with written informed consent undergo a structured assessment of symptoms, past medical history, family history and the presence of HCM-specific red flags. Clinical data derived from electrocardiogram, echocardiography, laboratory analysis, and genetic testing are collected and entered into a web-based, responsive electronic case report form. Bilateral data transfer agreements ensure legal protection of each site. Between March 2024 and May 2025, 7 University centers and 7 community hospitals from 6 out of 9 Austrian federal states were initiated. Overall, recruitment rate was 2.5 patients per site and month, with University centers and community hospitals contributing 92% and 8%. Among 303 enrolled participants, median age was 60 (25th, 75th percentile; 50, 68), 44% were women. Echocardiography, cardiac magnetic resonance imaging and genetic testing were available in 99%, 86% and 60%, respectively. In this first year, participating sites of the Austrian HCM Registry achieved a consistent and fast recruitment rate. Data availability is high and cohort characteristics align well with other registries. The Austrian HCM Registry will serve as a robust research platform providing contemporary real-world data on epidemiology, diagnosis and management of HCM in a Central European country. ClinicalTrials.gov identifier. NCT06368518.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.